Literature DB >> 2139920

Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.

M Seed1, F Hoppichler, D Reaveley, S McCarthy, G R Thompson, E Boerwinkle, G Utermann.   

Abstract

Familial hypercholesterolemia carries a marked increase in the risk of coronary heart disease (CHD), but there is considerable variation between individuals in susceptibility to CHD. To investigate the possible role of lipoprotein(a) as a risk factor for CHD, we studied the association between serum lipoprotein(a) levels, genetic types of apolipoprotein(a) (which influence lipoprotein(a) levels), and CHD in 115 patients with heterozygous familial hypercholesterolemia. The median lipoprotein(a) level in the 54 patients with CHD was 57 mg per deciliter, which is significantly higher than the corresponding value of 18 mg per deciliter in the 61 patients without CHD. According to discriminant-function analysis, the lipoprotein(a) level was the best discriminator between the two groups (as compared with all other lipid and lipoprotein levels, age, sex, and smoking status). Phenotyping for apolipoprotein(a) was performed in 109 patients. The frequencies of the apolipoprotein(a) phenotypes and alleles differed significantly between the patients with and those without CHD. The allele LpS2, which is associated with high lipoprotein(a) levels, was found more frequently among the patients with CHD (0.33 vs. 0.12). In contrast, the LpS4 allele, which is associated with low lipoprotein(a) levels, was more frequent among those without CHD (0.27 vs. 0.15). We conclude that an elevated level of lipoprotein(a) is a strong risk factor for CHD in patients with familial hypercholesterolemia, and the increase in risk is independent of age, sex, smoking status, and serum levels of total cholesterol, triglyceride, or high-density lipoprotein cholesterol. The higher level of lipoprotein(a) observed in the patients with CHD is the result of genetic influence.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139920     DOI: 10.1056/NEJM199005243222104

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  73 in total

1.  Clinical implications of elevated lipoprotein(a).

Authors:  A von Eckardstein; G Assmann
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

Review 2.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

3.  Lipoprotein(a) and coronary heart disease.

Authors:  M Seed; J Loscalzo
Journal:  BMJ       Date:  1992-08-22

4.  Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin.

Authors:  L Slunga; O Johnson; G H Dahlén
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

6.  Proceedings of the British Pharmacological Society. 12-14 September 1990, Belfast.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 7.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 8.  Lipoprotein(a): implications for clinical practice.

Authors:  Robert C Block; Thomas A Pearson
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

9.  Limited discriminant value of lipoprotein AI, lipoprotein Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease.

Authors:  D T Vallance; H A Staunton; A F Winder
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

10.  Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey.

Authors:  M F Laker; J P Reckless; D J Betteridge; P N Durrington; J P Miller; D P Nicholls; J Shepherd; G R Thompson
Journal:  J Clin Pathol       Date:  1992-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.